Avenna is a MedTech start up specializing on precision medicine solutions for early detection, prevention and treatments for chronic inflammatory diseases ( “CIDs”). We are a spin out from Oxford’ based company, Ludger, which has been innovating in the field of glycotechology for the last 20 years. At Avenna we work alongside scientists, clinicians, corporations and patients to enable successful translation of most promising of research grade technologies into practical biomarkers, tests and pathways for chronic inflammatory diseases ( “CID”). Our initial focus is on degenerative inflammatory diseases of the bowel.
Why? The global epidemic of chronic diseases. The World Health Organization (WHO) ranks chronic diseases as the greatest threat to human health. Worldwide, 3 of 5 people die due to chronic inflammatory diseases (CIDs) like stroke, chronic respiratory diseases, heart disorders, cancer, obesity, and diabetes. The costs of treating chronic diseases are growing and projected to reach $47 trillion by 2030.
How? Revolutionising how CIDs healthcare is performed. At Avenna we develop scalable precision medicine solutions, to enable early detection and treatment personalization for chronic inflammatory diseases (CIDs). Current commercial products and R&D pipeline focused around translation of GlyHealth medical technology into practical biomarkers, tests and pathways.
Products and services? Avenna-Regen Pathway for regenerative medicine treatment effectiveness of arthritic joints with stem cells. Avenna-IBD Pathway to predict and personalize treatments for flares in patients with inflammatory bowel diseases. These pathways incorporate GlyHealth medical glycomics technology that allows us to track and predict the course of chronic inflammatory processes. A patent had been submitted in Feb 2019.